Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer
Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable
FDA Approves Gleevec For First Line Rx Of CML
Fragmin Cuts Risk Of VE By 50 Percent In Study
Sirolimus-Containing Therapy Reduces GVHD, Study Finds
Avastin Regimen Bested Chemo Alone In Early Disease
Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca
Study Confirms Cancer Risk Increase Due To Combined HRT
Pill Associated With Cancer In BRCA1 Mutation Carriers
National Cancer Institute Lists Approved Clinical Trials
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?
